Recruiting
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.
ClinicalTrials.gov IDNCT07552922
PhaseNA
Enrollment24
SponsorSt Vincent's Hospital, Sydney
Age18 Years and older
SexMALE
Conditions studied
Prostate Cancer (Adenocarcinoma)
About this study
This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.
Interventions
- Other: Semi-structured Interview — this t study will use qualitative methods to explore men's views of gynaecomastia from high-risk BCR PCa treatments (Stage 1) to inform attributes and levels for a later DCE to examine patient treatment preferences (Stage 2).
Primary outcomes
- Number and content of themes and subthemes describing PCa patients' perceptions of the risk of breast-related side effects, including gynaecomastia, from high-risk BCR PCa treatment. (12 months)
Eligibility information
Inclusion Criteria:
* Men with high-risk BCR PCa but no ADT+/-ARPI experience.
* Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment.
Exclusion Criteria:
• Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.
Study locations
- Kinghorn Cancer Centre, Sydney, New South Wales 2010 Australia
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-28.